Drug delivery technologies can be classified on the basis of the four delivery routes: oral, transdermal, inhalation, and parenteral. These innovative technologies are highly useful in protein and gene-based therapies. Upcoming drug delivery technolo ....see more
The pen needles market is expected to grow from USD 1.3 Billion in 2021 to USD 2.2 Billion by 2026, at a compound annual growth rate (CAGR) of 11.2%. during the forecast period. Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Owen Mumford (UK), Terumo Corporation (Japan), Nipro Corporation (Japan) Allison Medical (US), AdvaCare Pharma (US), Berpu Medical Technology (China), ARKRAY (Japan), GlucoRx (UK), HTL-STREFA (Poland), UltiMed, (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Diabetes Care (Canada), Montmed (Canada), Trividia Health (US), VOGT Medical Vertrieb (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), Iyon (Turkey), Links Medical Products (US), and MHC Medical Products (US).
The Prefilled Syringes Market is expected to grow from USD 5.6 billion in 2020 to USD 8.6 billion by 2025, at a CAGR of 9.0% during the forecast period. Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US) are the key players in the global prefilled syringes market.
The Pharmaceutical Drug Delivery Market is expected to grow from USD 1,430.5 billion in 2020 to USD 2,015.3 billion by 2025, at a CAGR of 7.1% during the forecast period. The global pharmaceutical drug delivery market is highly competitive owing to the presence of several large and small players. Johnson & Johnson, Inc. (US), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (US), Bayer AG (Germany), Pfizer, Inc. (US), Novartis AG (Switzerland), 3M Company (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc, (UK), Sanofi (France), and Antares Pharma, Inc. (US) are some of the leading players operating in the pharmaceutical drug delivery market.
The global needles market is projected to reach USD 8.47 Billion by 2022 from USD 5.82 Billion in 2017, at a CAGR of 7.8% during the forecast period. The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.).
The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 Billion by 2021 from USD 9.81 Billion in 2016, at a CAGR of 15.5% during the forecast period. Growth in this market is mainly driven by growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, rising demand for biosimilars and vaccination, advantages of drug delivery technology, increasing demand for self-injection devices.
The overall market for syringes is expected to reach $15.99 billion by 2021 from $10.56 billion in 2016, at a CAGR of 8.7% during the forecast period. High prevalence of chronic diseases across the globe, rising geriatric population, increasing adoption of safety syringes, technological advancements, and increasing demand for vaccines are supporting the market growth of syringes. However, high cost of safety syringes and increasing incidence of needle stick injuries are the major challenges in global Market.
The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is primarily driven by the rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements. However, risk of needlestick injuries and side effects related to drugs are expected to restrain the growth of this market in the coming years.
The European injectable drug delivery market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. Factors such as rising prevalence of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements are driving the growth of this market. On the other hand, alternative delivery methods such as oral and transdermal, safety concerns, and blood-borne infections are hindering the growth of this market.
The Europeandrug delivery market was worth $39.9 billion in the year 2012. The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery.
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
This report analyzes the basic structure of the drug-device combination market and its various submarkets. Individual markets for major products such as anti-microbial catheters, wound-care products, bone-graft substitutes, bone cement, drug-eluting stents, photodynamic therapy, artificial pancreas, and steroid eluting electrodes are further broken down into their respective sub-segments based on products, technology and applications.